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Abstract
Fractalkine (FKN) and its receptor CX3CR1 are critical mediators in the vascular and tissue damage of several chronic
diseases, including systemic sclerosis (SSc) and pulmonary arterial hypertension (PAH). Interestingly, the V249I and T280M
genetic polymorphisms inﬂuence CX3CR1 expression and function. We investigated whether these polymorphisms are
associated with PAH secondary to SSc. CX3CR1 genotypes were analyzed by PCR and sequencing in 76 patients with limited
SSc and 204 healthy controls. PAH was deﬁned by colorDoppler echocardiography. Homozygosity for 249II as well as the
combined presence of 249II and 280MM were signiﬁcantly more frequent in patients with SSc compared to controls (17 vs
6%, p ¼ 0.0034 and 5 vs 1%, p ¼ 0.0027, respectively). The 249I and 280M alleleswereassociated with PAH (odd ratio [OR]
2.2, 95% conﬁdence interval [CI] 1.01–4.75, p ¼ 0.028 and OR 7.37, 95%CI: 2.45–24.60, p ¼ 0.0001, respectively). In
conclusion, the increased frequencies of 249I and 280M CX3CR1 alleles in a subgroup of patients with SSc-associated PAH
suggest a role for the fractalkine system in the pathogenesis of this condition. Further, the 249I allele might be associated with
susceptibility to SSc.
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Introduction
Systemic sclerosis (SSc) is an autoimmune disease of
unknown etiology characterized by microvascular
changes and progressive skin and visceral organ
ﬁbrosis. Vascular alterations and cellular inﬁltrations
in target tissues are early features in the course of the
disease (Prescott et al. 1992, Kraling et al. 1995) while
pulmonary arterial hypertension (PAH) is a common
complication of SSc, often with poor prognosis
(Brundage 1990, MacGregor et al. 2001). Recent
evidence indicates that chemokines produced by
endothelial cells induce leukocyte transvascular
migration ultimately leading to tissue damage in
several chronic diseases, including SSc (Atamas and
White 2003, Hussein et al. 2005). Fractalkine (FKN)
is a recently discovered chemokine, that acts as
adhesion molecule via its speciﬁc receptor CX3CR1
on leukocytes when in its membrane-bound form, but
also as chemotaxic stimulus when in its soluble form
after proteolytic cleavage (Bazan et al. 1997).
Importantly, an abnormal expression or function of
the FKN/CX3CR1 systemis believedto beinvolvedin
inﬂammatory conditions leading to vascular and tissue
damage (Ancuta et al. 2003, Umehara et al. 2004).
Two coding CX3CR1 single nucleotide poly-
morphisms (V249I, T280M) have been recently
described (Faure et al. 2000) with the 249I allele
associated with a reduced prevalence of athero-
sclerosis (McDermott et al. 2001, Moatti et al. 2001,
Ghilardi et al. 2004) possibly secondary to a
decreased afﬁnity of FKN to its receptor. Since a
role for FKN in PAH (Balabanian et al. 2002) and
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prompted by the need to identify patients with SSc
at risk for PAH, we studied whether genetic
variability of the FKN/CX3CR1 system could be
involved in SSc-associated PAH.
Materials and methods
Study population
Seventy six patients (74 females, mean ^ standard
deviation age 62 ^ 12 years) affected with limited SSc
according to the classiﬁcation of LeRoy et al. (1988)
were enrolled in the study. All patients fullﬁlled the
American College of Rheumatology criteria for SSc
diagnosis (Preliminary criteria for the classiﬁcation of
systemic sclerosis (scleroderma). Subcommittee for
scleroderma criteria of the American Rheumatism
Association Diagnostic and Therapeutic Criteria
Committee 1980), and underwent colorDoppler
echocardiography for the deﬁnition of PAH. A
pulmonary artery systolic pressure (PASP) .35mm
Hg was used to deﬁne PAH (Schachna et al. 2003).
Sex-matched healthy subjects with no evidence of
cardiovascular diseases (n ¼ 204) served as controls.
DNA extraction and CX3CR1 genotyping
Following informed consent, whole blood was
obtained from all SSc cases and controls. DNA
extraction and CX3CR1 genotyping were performed
as previously described (Ghilardi et al. 2004).
Statistical analysis
Differences in genotype and allele frequencies
between groups were compared using the chi-square
test. Odds ratios (OR) (approximate relative risk) and
95% conﬁdence interval (CI) were calculated for the
associations of the V249I and T280M genotypes with
phenotypes. All analyses were two-tailed and P values
lower than 0.05 were considered as statistically
signiﬁcant. Stata Statistical Software (Stata Corpo-
ration, College Station, TX) was used for statistical
analyses.
Results
The genotype distributions for both I249V and
T280M polymorphisms was in accordance with the
Hardy-Weinberg law among control subjects but not
in patients with SSc where excesses of 249II
(p ¼ 0.002) and 280MM (p ¼ 0.018) were observed.
The adjusted ORs associated with the presence of
249I and the 280M alleles were 3.30 (95%CI: 1.30–
8.32, p ¼ 0.0034) and 1.22 (95%CI: 0.65–2.33,
p ¼ 0.50), respectively (Table I).
Six genotype combinations were possible when
I249V and T280M genotypes were combined
(Table II). Combinations 1 (249VV and 280TT)
and 6 (249VI and 280TM) were the most common in
both populations while combination 3 (249II and
Table I. Odd ratios for genotypes were calculated with V/I þ V/V vs I/I and T/M þ T/T vs M/M.
Patients
(No. 76)
Controls
(No. 204)
OR
(95% CI) P
V249I
V/V 42 (55%) 108 (53%)
V/I 21 (28%) 84 (41%)
I/I 13 (17%) 12 (6%) 3.30 (1.30-8.32) 0.0034
I allele frequency 0.31 0.27 1.24 (0.80-1.90) 0.29
T280M
T/T 56 (74%) 142 (70%)
T/M 16 (21%) 58 (28%)
M/M 4 (5%) 4 (2%) 1.22 (0.65-2.33) 0.50
M allele frequency 0.16 0.16 1.02 (0.60-1.79) 0.91
Table II. Combined genotype frequencies of the V249I and T280M polymorphisms of the CX3CR1 in systemic sclerosis patients and
controls.
Combined genotype V249I T280M Patients No (%) Controls No (%) P
1 VV TT 42 (56) 104 (51) Ns
2 II TT 5 (6) 4 (2) 0.05
3 II MM 4 (5) 2 (1) 0.027
4 II TM 4 (5) 6 (3) Ns
5 VI TT 9 (12) 36 (18) Ns
6 VI TM 12 (16) 52 (25) 0.08
Global haplotype effect x
2 ¼ 12.85, p ¼ 0.027.
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patients with SSc compared to controls (p ¼ 0.027).
Table III shows the relationship between CX3CR1
polymorphisms and the presence of PAH. The 249II
genotype was found in 8/26 (30%) patients with SSc-
associated PAH and 5/50 (10%) of patients with PASP
values ,35mmHg and such genotype was, therefore,
signiﬁcantly associated with PAH (OR 4, 95% CI
0.97–17.43; p ¼ 0.022). Accordingly, the 249I allele
frequency was signiﬁcantly higher in patients with
PAH (0.42 vs. 0.25 in patients without PAH, OR 2.2;
95% CI 1.01–4.75, p ¼ 0.028). Finally, the 380MM
genotype was observed in 4/26 patients with PAH and
0/50 patients with normal PASP values (p ¼ 0.004).
Discussion
SSc is an enigmatic autoimmune disease burdened by
several types of serious complications. Among these,
isolated PAH is more frequent in the limited form of
SSc (Koh et al. 1996) and its prognosis is often poor,
particularly because of elusive and late diagnosis and
despite the available novel treatments (Badesch et al.
2004; McLaughlin et al. 2004), thus representing the
most frequent cause of death in limited SSc
(MacGregor et al. 2001). For these reasons, a non-
invasive marker to speciﬁcally identify patients who
are more prone to developing PAH should be a
primary goal of SSc research.
There is increasing evidence for a role of
chemokines in initiating and perpetuating endothelial
cell activation as one of the key events leading to tissue
damage in several vascular diseases, including SSc
(Fujii et al. 2004). A link between endothelial cell
dysfunction and the early cellular inﬁltration across
the vessel wall into SSc-targeted tissues has been
demonstrated (Prescott et al. 1992) while other
reports have shown an upregulated leukocyte trafﬁck-
ing into SSc connective tissues (Rudnicka et al. 1992).
Importantly, FKN is one of the most potent molecules
that regulate inﬂammatory cell trafﬁcking through the
endothelium (Fong et al. 1998) and recent ﬁndings
suggest a possible role for the FKN/CX3CR1 system
in SSc pathogenesis (Hasegawa et al. 2005). Similar to
SSc, leukocyte trafﬁcking with extravasation in
response to chemokines plays a role in PAH
pathogenesis (Dorfmuller et al. 2002) and pulmonary
perivascular inﬂammatory inﬁltrates of patients with
SSc-associated PAH (Cool et al. 1997) indicate a
possible role for vascular inﬂammation also in SSc-
related PAH. Further, Balabanian et al. have
suggested a major role for FKN/CX3CR1 in PAH
pathogenesis, since they demonstrated that T cells
from patients with PAH have upregulated CX3CR1,
alongside with high FKN plasma concentrations,
FKN hyper-expression in lung parenchyma and
pulmonary artery endothelial cells.
For these reasons, wehave performed a case-control
association study to determine if CX3CR1 genetic
polymorphisms were associated with SSc and SSc-
associated PAH. Our data indicate that 429I allele and
480M allele frequencies are signiﬁcantly increased in
SSc patients with PAH, thus supporting the obser-
vations of Balabanian et al. and suggesting that
FKN/CX3CR1 system might play a role also in SSc-
associated PAH pathogenesis, albeit in a small
subgroup of patients with SSc. On the other hand,
we observed that 249II genotype is associated with
susceptibility to SSc.
Interestingly, CX3CR1 polymorphisms were shown
toexertaprotectiveeffectagainstcoronaryandcarotid
atherosclerosis (McDermott et al. 2001; Moatti et al.
2001;Ghilardi etal.2004),thus apparentlyconﬂicting
with our ﬁndings. The reasons for this apparent
discrepancy might be rather complex, similar to the
FKN/CX3CR1 pathway (Daoudi et al. 2004) and
severalissuesneedtobeaddressed.First,theprotective
effectof249Ioncoronaryarterieshasbeenreportedto
be associated with a lower number of cell surface
binding sites, although highly variable among individ-
uals with the same genotype (Moatti et al. 2001) while
the resulting lower FKN afﬁnity has been recently
questioned, being the 249I homozygous genotype
associated with enhanced adhesiveness (Daoudi et al.
2004). Also, we note that a clear deﬁnition of the
speciﬁc polymorphism contribution is difﬁcult since
they are in linkage disequilibrium. Second, differences
related to the characteristics of speciﬁc tissue vessels
Table III. 3. Odds ratios for genotypes were calculated with V/I þ V/V vs I/I and T/M þ T/T vs M/M.
PASP ,35mm Hg
N=50 (n)
PASP .35mm Hg,
N=26 (n) OR (95%CI) P
V/V 30 (60%) 12 (47%)
V/I 15 (30%) 6 (23%)
I/I 5 (10%) 8 (30%) 4 (0.97–17.43) 0.022
I allele frequency 0.25 0.42 2.2 (1.01–4.75) 0.028
T/T 44 (88%) 12 (46%)
T/M 6 (12%) 10 (38%)
M/M 0 (0%) 4 (15%) 0.004
M allele frequency 0.06 0.35 7.37 (2.45–24.6) 0.0001
Fractalkine receptor in systemic sclerosis 277cannot be overlooked. In fact, the same CX3XR1
genotypes were not protective against ischaemic stroke
(Hattori et al. 2005; Lavergne et al. 2005), nor against
peripheralarterialdisease(Gugletal.2003),butinthe
same patients I249 and M280 alleles were associated
both with an increased risk of brain infarction and a
reduced frequencyof cardiovascular history (Lavergne
et al. 2005). Third, we cannot rule out at present that
other aspects of the FKN/CX3CR1 system might be
interplaying. Lucas et al. reported that FKN has a role
in vascular remodelling through the recruitment of
smooth muscle cells, a prominent histological feature
of both PAH and SSc. Further, remodelling is
regulated by oxygen levels through the regulation of
the expression of vasoactive substances and smooth
muscle mitogens (Faller 1999) and the interference
with mechanisms of angiogenesis (Koch 2000).
Interestingly, hypoxia can inhibit FKN expression
(Yamashita et al. 2003) while also functioning as an
angiogenic mediator (Volin et al. 2001) thus possibly
contributing either to the altered angiogenesis and the
ischaemic changes of SSc vasculopathy (LeRoy 1996)
or to the pulmonary arterial lesions of PAH. Fourth,
the mechanisms underlying atherosclerosis formation
are likely different from those leading to the vascular
r e m o d e l l i n go b s e r v e di nS S ca n dP A H ,w h e r e
pathological resemblance (Tuder et al. 1994; Cool
et al. 1997) might suggest a similar pathogenesis of the
tissue injury.
WefailedtoidentifyanassociationbetweenCX3CR1
polymorphisms and pulmonary ﬁbrosis (data not
shown); Hasagawa et al. reported signiﬁcantly elevated
plasma FKN levels in patients with SSc-associated
pulmonary ﬁbrosis but not in those with PAH. This
discrepancy may be due to the small number of limited
SSc, coupled with the well known higher prevalence of
pulmonary ﬁbrosis in diffuse SSc (Steen 2003). In our
study,theobjectiveofstudyingPAHmadethechoiceof
enrolling patients with limited SSc more appropriate.
Future studies are warranted to conﬁrm the
proposed association, as well as to better deﬁne
the role of the FKN/CX3CR1 system in SSc and other
diseases characterized by vascular inﬂammation
and remodelling. In the case of SSc, the search for
non-invasive markers of disease progression or
severity should be a priority not only because an
early diagnosis may improve SSc-associated PAH
prognosis, but also because chemokines and their
receptors might provide novel therapeutic targets.
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